Discover
PVLA
Palvella Therapeutics, Inc.
138.26
2 x 106.59
2 x 175.20
bid
ask
-
14.56
9.53%
2 @ 04:00 PM
138.27 +0.01 (0.01%)
| Ytd | 32.09% | |
| 1y | 509.88% |
135.00
day range
150.08
22.03
52 week range
161.38
| Open | 150.00 | Prev Close | 152.82 | Low | 135.00 | High | 150.08 | Mkt Cap | 1.98B |
| Vol | 417.31K | Avg Vol | 263.35K | EPS | -4.17 | P/E | N/A | Forward P/E | -20.28 |
| Beta | N/A | Short Ratio | 8.17 | Inst. Own | 96.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 120.57 | 200-d Avg | 100.93 | 1yr Est | 229.60 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0 | N/A | -0.3 | -33.33% |
| 2026-03-31 | 2025-12 | 0 | N/A | -0.13 | -13.68% |
| 2025-11-11 | 2025-09 | 0 | N/A | -0.18 | -21.18% |
| 2025-08-14 | 2025-06 | 0 | N/A | -0.08 | -10.26% |
| 2025-05-15 | 2025-03 | 0 | N/A | 2.66 | 78.24% |
| 2025-03-31 | 2024-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-21 | Stephens & Co. | Upgrade | Overweight | Overweight |
| 2026-05-21 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-05-12 | Stephens & Co. | Upgrade | Overweight | |
| 2026-03-31 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-03-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-03-16 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-11 | ADAR1 CAPITAL MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-06-16 | GOIN KATHLEEN | Chief Operating Officer | 0.00 | Sale |
| 2026-02-26 | HERON ELAINE J | Director | 53.69K | Purchase |
| 2026-03-29 | JENKINS GEORGE M | Director | 201.13K | Purchase |
| 2026-06-11 | KORENBERG MATTHEW E | Chief Financial Officer | 1000 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Suvretta Capital Management, LLC | 1.15M | 159.48M | 8.04% |
| 2026-03-30 | First Light Asset Management, LLC | 980.76K | 135.60M | 6.84% |
| 2026-03-30 | BVF Inc. | 960.99K | 132.87M | 6.70% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 882.40K | 122.00M | 6.15% |
| 2026-03-30 | Blackrock Inc. | 686.85K | 94.96M | 4.79% |
| 2026-03-30 | Jennison Associates LLC | 640.61K | 88.57M | 4.47% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 361.69K | 50.01M | 2.52% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 303.54K | 41.97M | 2.12% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 276.56K | 38.24M | 1.93% |
| 2026-03-30 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 231.48K | 32.00M | 1.61% |
| 2026-02-27 | Prudential Sector Funds, Inc.-PGIM Jennison Health Sciences Fund | 183.04K | 25.31M | 1.28% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 181.99K | 25.16M | 1.27% |